Javelin Pharmaceuticals Inc. (Public, AMEX:JAV) The follow article has been submitted to StocksHaven Investments by Nicholas DeCesare, a highly respected investor and journalist within the biopharma realm. Take one look at a chart of Javelin Pharmaceuticals over the past six months and you will see a stock that has doubled in price but still sits [...]



